KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) EPS (Basic) (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of EPS (Basic) readings, the most recent being $1.17 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 1000.0% to $1.17 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.25, a 390.7% increase, with the full-year FY2025 number at $1.26, up 393.02% from a year prior.
  • EPS (Basic) hit $1.17 in Q4 2025 for Biocryst Pharmaceuticals, up from $0.06 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.17 in Q4 2025 to a low of -$0.4 in Q1 2022.
  • Median EPS (Basic) over the past 5 years was -$0.21 (2022), compared with a mean of -$0.14.
  • Biggest five-year swings in EPS (Basic): crashed 280.0% in 2022 and later soared 1000.0% in 2025.
  • Biocryst Pharmaceuticals' EPS (Basic) stood at -$0.1 in 2021, then crashed by 280.0% to -$0.38 in 2022, then grew by 18.42% to -$0.31 in 2023, then surged by 58.06% to -$0.13 in 2024, then surged by 1000.0% to $1.17 in 2025.
  • The last three reported values for EPS (Basic) were $1.17 (Q4 2025), $0.06 (Q3 2025), and $0.02 (Q2 2025) per Business Quant data.